Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenue
The strong performance the company has delivered in Q2 reflected the strength of the business fundamentals, sustained execution and the resilience of its diversified product portfolio.
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Published - November 05, 2026 04:37 pm IST - HYDERABAD
Aurobindo Pharma’s consolidated net profit for the quarter ended September rose 32.5% year-on-year (YoY) to ₹1,124 crore on higher revenue across markets and business segments.
The profit came on a 24% increase in revenue from operations to ₹10,263 crore.
It is the highest ever quarterly revenue thus far and driven by growth across businesses.
The company has declared an interim dividend of ₹7 per share.
On a sequential basis, however, the growth was subdued.
Aurobindo Pharma had reported ₹1,032 net profit and ₹9,150 revenue in the June quarter.
Vice-Chairman and Managing Director K.
Nithyananda Reddy said the strong performance the company has delivered in Q2 reflected the strength of the business fundamentals, sustained execution and the resilience of its diversified product portfolio.
“Our growth is supported by healthy organic momentum across our key businesses and the successful integration of inorganic opportunities, further strengthening our capabilities and positioning us for the future,” he said.
The company said during the quarter the U.S. revenue increased 25% YoY to ₹4,555 crore; Europe by 27% to ₹3,161 crore; Growth Markets by 16% to ₹1,026 crore.
Total formulations revenue stood at ₹9,102 crore (₹7,325 crore), while API revenue touched ₹1,162 crore (₹961 crore).
business (general) / pharmaceutical / medicine / earnings / company information
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences.
They cannot be abusive or personal.
Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform.
If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles.
If you do not have an account please register and login to post comments.
Users can access their older comments by logging into their accounts on Vuukle.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news
